Risk of End-Stage Renal Disease and Death After Cardiovascular Events in Chronic Kidney Disease

被引:73
|
作者
Sud, Maneesh [1 ]
Tangri, Navdeep [5 ]
Pintilie, Melania [3 ,6 ]
Levey, Andrew S. [7 ]
Naimark, David [1 ,2 ,4 ]
机构
[1] Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Nephrol, Toronto, ON M4N 3M5, Canada
[3] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M4N 3M5, Canada
[4] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON M4N 3M5, Canada
[5] Univ Manitoba, Oaks Gen Hosp 7, Div Nephrol, Winnipeg, MB, Canada
[6] Univ Hlth Network, Dept Biostat, Toronto, ON, Canada
[7] Tufts Med Ctr, Div Nephrol, Boston, MA USA
关键词
cardiovascular diseases; epidemiology; kidney; mortality; HEART-FAILURE; FOLLOW-UP; PROGNOSTIC-SIGNIFICANCE; MYOCARDIAL-INFARCTION; UNITED-STATES; CARE UNITS; ALL-CAUSE; MORTALITY; OUTCOMES; POPULATION;
D O I
10.1161/CIRCULATIONAHA.113.007106
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Patients with chronic kidney disease stages 3 to 5 (glomerular filtration rate <60 mL/min/1.73m(2)) are at increased risk of cardiovascular (CV) disease when compared with patients with less severe chronic kidney disease. How CV events modify the subsequent risk of progression to end-stage-renal disease (ESRD) or all-cause mortality (ACM) before ESRD is not well known. Methods and Results-This retrospective cohort study involved 2964 chronic kidney disease subjects referred between January 2001 and December 2008 to the nephrology clinic at Sunnybrook Health Sciences Center, Toronto, Ontario. Interim CV events (heart failure, myocardial infarction, and stroke), ESRD, and ACM were ascertained from administrative data. Over a median follow-up time of 2.76 years (interquartile range, 1.45-4.62), 447 (15%) subjects had a CV event. In the same time period, 318 (11%) developed ESRD, and 446 (15%) experienced ACM before ESRD (156 [5%] from a CV and 290 [10%] from a non-CV-related cause). When analyzed as a time-dependent variable, an interim CV event was associated with a higher risk of subsequent ESRD (hazard ratio, 5.33; 95% confidence interval, 3.74-7.58) and ACM before ESRD (hazard ratio, 4.15, hazard ratio, 3.30-5.23). The hazard ratio for CV-related death versus non-CV-related death before ESRD was 12.38 (95% confidence interval, 8.30-18.45) versus 2.13 (95% confidence interval, 1.57-2.87). Conclusions-CV events are common in patients with chronic kidney disease stages 3 to 5 and are associated with a substantial increase in the risk of ESRD and ACM before ESRD. Intensive primary and secondary prevention strategies may help attenuate this risk.
引用
收藏
页码:458 / +
页数:40
相关论文
共 50 条
  • [41] Incidence of end-stage renal disease and death among insured African Americans with chronic kidney disease
    Derose, Stephen F.
    Rutkowski, Mark P.
    Levin, Nathan W.
    Liu, In-Lu A.
    Shi, Jiaxiao M.
    Jacobsen, Steven J.
    Crooks, Peter W.
    [J]. KIDNEY INTERNATIONAL, 2009, 76 (06) : 629 - 637
  • [42] Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease
    Li S.
    Foley R.N.
    Collins A.J.
    [J]. International Urology and Nephrology, 2005, 37 (2) : 395 - 402
  • [43] Diuretic use in stage 5 chronic kidney disease and end-stage renal disease
    Sica, DA
    Gehr, TWB
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2003, 12 (05): : 483 - 490
  • [44] No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease
    Mehrotra, Rajnish
    Peralta, Carmen A.
    Chen, Shu-Cheng
    Li, Suying
    Sachs, Michael
    Shah, Anuja
    Norris, Keith
    Saab, Georges
    Whaley-Connell, Adam
    Kestenbaum, Bryan
    McCullough, Peter A.
    [J]. KIDNEY INTERNATIONAL, 2013, 84 (05) : 989 - 997
  • [45] Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease
    Vlad, Cristiana-Elena
    Foia, Liliana
    Popescu, Roxana
    Ivanov, Iuliu
    Luca, Mihaela Catalina
    Delianu, Carmen
    Toma, Vasilica
    Statescu, Cristian
    Rezus, Ciprian
    Florea, Laura
    [J]. JOURNAL OF DIABETES RESEARCH, 2019, 2019
  • [46] Cardiovascular risk in diabetic end-stage renal disease patients
    Wang, Angela Yee-Moon
    [J]. JOURNAL OF DIABETES, 2011, 3 (02) : 119 - 131
  • [47] Cardiovascular risk in end-stage renal disease: vascular aspects
    London, GM
    Marchais, SJ
    Metivier, F
    Guerin, AP
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 : 97 - 104
  • [48] The challenge of cardiovascular risk factors in end-stage renal disease
    Covic, A
    Gusbeth-Tatomir, P
    Goldsmith, DJA
    [J]. JOURNAL OF NEPHROLOGY, 2003, 16 (04) : 476 - 486
  • [49] The epidemic of cardiovascular disease in end-stage renal disease
    Brenner, RM
    Wrone, EM
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1999, 8 (03): : 365 - 369
  • [50] Cardiovascular disease in end-stage renal disease patients
    Collins, AJ
    Li, SL
    Ma, JZ
    Herzog, C
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) : S26 - S29